Current and potential therapeutic uses of lanthanide radioisotopes

被引:92
作者
Cutler, CS
Smith, CJ
Ehrhardt, GJ
Tyler, TT
Jurisson, SS
Deutsch, E
机构
[1] Univ Missouri, Res Reactor, Columbia, MO 65211 USA
[2] Univ Missouri, Dept Chem, Columbia, MO 65211 USA
关键词
lanthanides; radiotherapy;
D O I
10.1089/cbr.2000.15.531
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In the last 25 years, diagnostic nuclear medicine has come to depend an the versatile chemistry of a single radioisotope, technetium-99m (Tc-99m), Different chelating molecules can be used to guide Tc-99m through various physiological path ways in the body to gain information about disease scares. No single radioisotope similarly dominates therapeutic applications. In the field of radioisotope therapy, much discussion and debate have focused on what radioisotope might be "ideal" for treatment of malignant tumors. The ideal may not be a single radioisotope, but rather the class of very closely related radiolanthanides and lanthanide-like radioisotopes. These radioisotopes possess strikingly similar chemistries and thus all may be conjugated to biomolecules using a single chelate, the DOTA moiety land ifs chemical analogs). They also provide a wide range of physical characteristics, such as half-lives and beta energies, that can be chosen to march the biological properties of the conjugated biomolecule and the malignant tumor. Thus, the radiolanthanide-DOTA bioconjugate model provides a set of physically diverse, but chemically very similar, therapeutic radiopharmaceutical agents, the individual members of which can be tailored to treat specific types of cancers.
引用
收藏
页码:531 / 545
页数:15
相关论文
共 55 条
  • [1] Anderson CJ, 1998, J NUCL MED, V39, P1944
  • [2] ANDERSON CJ, 1995, J NUCL MED, V36, P2315
  • [3] BAKKER WH, 1991, J NUCL MED, V32, P1184
  • [4] BAYOUTH JE, 1995, J NUCL MED, V36, P730
  • [5] Preparation and biodistribution of copper-67-labeled porphyrins and porphyrin-A6H immunoconjugates
    Bhalgat, MK
    Roberts, JC
    MercerSmith, JA
    Knotts, BD
    Vessella, RL
    Lavallee, DK
    [J]. NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (02): : 179 - 185
  • [6] BACKBONE-SUBSTITUTED DTPA LIGANDS FOR Y-90 RADIOIMMUNOTHERAPY
    BRECHBIEL, MW
    GANSOW, OA
    [J]. BIOCONJUGATE CHEMISTRY, 1991, 2 (03) : 187 - 194
  • [7] SYNTHESIS OF 1-(PARA-ISOTHIOCYANATOBENZYL) DERIVATIVES OF DTPA AND EDTA - ANTIBODY LABELING AND TUMOR-IMAGING STUDIES
    BRECHBIEL, MW
    GANSOW, OA
    ATCHER, RW
    SCHLOM, J
    ESTEBAN, J
    SIMPSON, DE
    COLCHER, D
    [J]. INORGANIC CHEMISTRY, 1986, 25 (16) : 2772 - 2781
  • [8] RADIOIODINATED SOMATOSTATIN ANALOG RC-160 - PREPARATION, BIOLOGICAL-ACTIVITY, IN-VIVO APPLICATION IN RATS AND COMPARISON WITH [I-123-TYR(3)]OCTREOTIDE
    BREEMAN, WAP
    HOFLAND, LJ
    BAKKER, WH
    VANDERPLUIJM, M
    VANKOETSVELD, PM
    DEJONG, M
    SETYONOHAN, B
    KWEKKEBOOM, DJ
    VISSER, TJ
    LAMBERTS, SWJ
    KRENNING, EP
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1993, 20 (11): : 1089 - 1094
  • [9] STRUCTURE AND SOLUTION STABILITY OF INDIUM AND GALLIUM COMPLEXES OF 1,4,7-TRIAZACYCLONONANETRIACETATE AND OF YTTRIUM COMPLEXES OF 1,4,7,10-TETRAAZACYCLODODECANETETRAACETATE AND RELATED LIGANDS - KINETICALLY STABLE COMPLEXES FOR USE IN IMAGING AND RADIOIMMUNOTHERAPY - X-RAY MOLECULAR-STRUCTURE OF THE INDIUM AND GALLIUM COMPLEXES OF 1,4,7-TRIAZACYCLONONANE-1,4,7-TRIACETIC ACID
    BROAN, CJ
    COX, JPL
    CRAIG, AS
    KATAKY, R
    PARKER, D
    HARRISON, A
    RANDALL, AM
    FERGUSON, G
    [J]. JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1991, (01): : 87 - 99
  • [10] CHINOL M, 1993, J NUCL MED, V34, P1536